We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Akcea Therapeutics, Inc. (“Akcea” or the “Company”) (NASDAQ: AKCA) to Ionis Pharmaceuticals, Inc. (“Ionis”) (NASDAQ: IONS). Under the terms of the agreement, Ionis will commence a tender offer for all outstanding shares of Akcea common stock not already owned by Ionis at a price of $18.15 per share in cash.
The Akcea merger investigation concerns whether the Board of Akcea has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.
To receive more information, please fill out the form.